Quantcast

Latest German inventions Stories

2011-07-21 08:30:00

FRAZER, Pa., July 21, 2011 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA® (fentanyl buccal tablet) [C-II] and ACTIQ® (oral transmucosal fentanyl citrate) [C-II]. Both products are indicated for the management of breakthrough pain in opioid-tolerant patients with cancer. Under this REMS, pharmacies and healthcare...

2011-07-20 15:00:00

MORRISTOWN, N.J., July 20, 2011 /PRNewswire/ -- Actavis, an international generic pharmaceutical company, today announced that it has begun shipping Oxymorphone Hydrochloride Extended-Release Tablets, CII 7.5mg and 15mg, a generic equivalent of Opana ER®. The 7.5mg and 15mg strength of Opana ER had U.S. total sales of approximately $21.9 million for the 12 months ending March 31, 2011, according to IMS Health. Commenting on the launch, Michael Perfetto, Vice...

2011-07-20 14:57:14

Vaccine may hold promise for those who want to break their heroin addiction Researchers at The Scripps Research Institute have developed a highly successful vaccine against a heroin high and have proven its therapeutic potential in animal models. The new study, published recently online ahead of print by the American Chemical Society's Journal of Medicinal Chemistry, demonstrates how a novel vaccine produces antibodies (a kind of immune molecule) that stop not only heroin but also other...

2011-07-18 03:45:00

SYDNEY and BEDMINSTER, N.J., July 18, 2011 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today initiation of the New Drug Application (NDA) approval process for MoxDuo IR with the United States Food and Drug Administration (FDA). This NDA submission sets the stage for the regulatory approval process for MoxDuo IR for the treatment of moderate to severe acute pain, a $2.5 billion segment of the $8 billion spent annually on prescription opioids in the US. MoxDuo...

2011-07-05 16:14:00

BEVERLY HILLS, Calif., July 5, 2011 /PRNewswire/ -- Dr. Michael Lowenstein, co-medical director of The Waismann Method, an advanced procedure for rapid opiate detoxification under deep sedation, is expressing grave concern over the implications of a new report that outlines the alarming rise in number of individuals seeking treatment for opioid dependence, for example OxyContin addiction. The new national analysis from the U.S. Substance Abuse and Mental Health Services Administration...

2011-06-30 17:03:00

READING, England and BEDMINSTER, N.J., June 30, 2011 /PRNewswire/ -- Archimedes Pharma Ltd., and its subsidiary, Archimedes Pharma U.S. Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Lazanda® (fentanyl) nasal spray for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Lazanda marks the first FDA...

2011-06-29 07:40:00

More comprehensive statistical analysis shows MoxDuo IR, at equi-analgesic doses to either Morphine or Oxycodone, produced significantly less severe respiratory depression SYDNEY and BEDMINSTER, N.J., June 29, 2011 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the release of additional data on its Phase 3 safety study for MoxDuo IR. Study 022 compared the respiratory effects of MoxDuo IR to equi-analgesic doses of either morphine or oxycodone in...

2011-06-28 04:53:00

LONDON, June 28, 2011 /PRNewswire/ -- Stronger and Effective for Longer Versus Standard Paracetamol Tablets, as Shown in a Dental Pain Study[1] A new non-prescription painkiller is now available in pharmacies across the UK, heralding the first UK painkiller combination of ibuprofen and paracetamol in 'over-the-counter' pain relief. NUROMOL is the UK's first clinically-proven painkiller to combine the power of ibuprofen and paracetamol in one tablet. In a dental pain...

2011-06-24 16:12:00

CHADDS FORD, Pa., June 24, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today issued a voluntary nationwide consumer level recall of Endocet® (oxycodone/acetaminophen, USP) Tablets, 10 mg/325 mg 100 count bottles, NDC 60951-712-70, Lot # 402415NV and #402426NV. One bottle from each lot of Endocet® (oxycodone/acetaminophen, USP) Tablets, 10 mg/325 mg, Lot # 402415NV and # 402426NV, NDC 60951-712-70, 100 count bottles, was found to contain some...

2011-06-23 15:45:00

CHADDS FORD, Pa., June 23, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today that it received notification from the U.S. Food and Drug Administration (FDA) that Endo's complete response to the FDA's Jan. 7, 2011 Action Letter relating to Endo's new drug application (NDA) for a new formulation of OPANA ER has been accepted. The new formulation was developed in partnership with Grunenthal GmbH and is designed to provide some resistance to certain types of product...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'